



STAR GRYPHON

Glycaemic Control for Neonatal Intensive Care Units


Performance and safety of STAR glycaemic control in the NICU : clinical results, including results from a new protocol implementation

Jennifer Dickson, Adrienne Lynn, Cameron Gunn, Aaron Le Compte, Liam Fisk, Geoffrey Shaw, J. Geoffrey Chase





A glycaemic control fairy tale?



The damsel
in distress



The evil
Stepmother



Abnormal
Blood sugar




The Hero



GRYPHON



The
Noble Steed



SI: Insulin Sensitivity!



The
Happy Ending



A STAR glycaemic control framework



The very premature infant: a damsel in distress



The damsel
in distress



The damsel :

- Very premature infant (<31 weeks GA)
- Extremely premature infant (<28 weeks GA)

The distress (and there is a lot of it):

- Not fully developed
- High risk of:
 - sever infection (sepsis)
 - Brain haemorrhage
 - Retinopathy of prematurity
- High dependence on
 - Intensive care
 - Mechanical Ventilation
 - Intravenous nutrition



Abnormal blood sugar: the evil step mother



Abnormal Blood Glucose:

- **Hyperglycaemia** (Elevated blood glucose concentrations)
- **Hypoglycaemia** (Low blood glucose concentrations)

Associated effects of hyperglycaemia in neonates

- Worsened outcomes
- Increased mortality
- Increased :
 - hospital length of stay
 - dependence on mechanical ventilation
- Increased risk of:
 - sepsis
 - brain haemorrhaging
 - retinopathy of prematurity



The evil
Stepmother

**Abnormal
Blood sugar**



Abnormal blood sugar: the evil step mother



Why is glycaemic control hard?

Hypoglycaemia (low blood sugar) is also dangerous

- Brain damage
- Developmental delays
- Higher mortality and morbidity

"Humans are horribly variable"

Variation in glycaemic metabolics:

- Over time
- Between patients



The evil
Stepmother

**Abnormal
Blood sugar**



Glycaemic control



Hyperglycaemia



Hypoglycaemia



The Quest: GLYCAEMIC CONTROL



Common treatments for hyperglycaemia:

Reduce Nutrition → at cost of weight gain and development

Use Insulin → at risk of driving blood sugar levels too low!



The evil
Stepmother

Abnormal
Blood sugar



THE QUEST:

→ Dose insulin in a way that is safe and allows the infants nutritional needs to be met!

→ Personalised, predictive, and preventative medicine

-accounting for the differences between patients, and changing patient condition over time





The Hero: STAR-GRYPHON

Model-based glycaemic control protocol for intensive care patients

- Glycaemic control: Targeting a blood glucose range of 4-8 mmol/L
- Model-based: use mathematics to describe and predict glucose and insulin response to therapy
- Interface: touch screen bedside tablet computer

STAR – Stochastic TARgeted glycaemic control:

Applications in

- Adult intensive care
- **GRYPHON**: specialized application for neonatal intensive care

(Glucose Regulation sYstem to Prevent Hyper- and hypO-glycaemia in Neonates)



The Hero



GRYPHON



Getting to know the HERO



The Hero



GRYPHON

The next few slides outline:

- The basics of the physiological model
- What insulin sensitivity is
- How insulin sensitivity is used to predict changes in BG

Common abbreviations:

- BG: Blood Glucose concentration
- SI: insulin sensitivity



Not just a pretty face: The Physiological Model


Using mathematics to describe physiological changes in insulin and glucose



The Hero



GRYPHON





The Model – INSULIN

Model describes both peripheral and plasma insulin.....



The Hero



GRYPHON

PERIPHERAL
INSULIN

$$\dot{Q} = n_I(I(t) - Q(t)) - n_c \frac{Q(t)}{1 + \alpha_G Q(t)}$$

degradation

Diffusion between
plasma and
periphery

PLASMA INSULIN

$$\dot{I} = -n_K I(t) - \frac{n_L I(t)}{1 + \alpha_I I(t)} - n_I(I(t) - Q(t)) + \frac{u_{ex}(t)}{V_{I,frac} * m_{body}} + (1 - x_L) u_{en}$$

Kidney
clearance

Kidney

Liver
clearance

Liver

First pass hepatic
extraction

Exogenous
insulin

Pancreas

Pancreatic
Insulin
Secretion



The Model – BLOOD GLUCOSE


Insulin sensitivity!



The Hero




GRYPHON






The Noble Steed: INSULIN SENSITIVITY

SI



The Noble Steed



SI: Insulin Sensitivity!


“Whole-body” insulin sensitivity

Fitted from clinical data - hour to hour

→ **Varies over time and between patients**

Captures the bodies overall blood glucose response to nutrition and insulin treatments

→ **Treatment independent**




SI profile from recent Christchurch NICU patient




The Noble Steed: INSULIN SENSITIVITY


SI



The Noble Steed



SI: Insulin Sensitivity!



Insulin Sensitivity is NOT proportional to BG

→ Can have **same SI** and **different BG** levels within and between patients

Insulin sensitivity describes **responsiveness to insulin**

Typically:

SI ↑ - BG ↓


SI ↓ - BG ↑

→ Therefore it is safer to dose insulin based on BG and SI, than on BG alone




INSULIN SENSITIVITY - Forecasting

SI



The Noble Steed




SI: Insulin Sensitivity!

Use population data to forecast

→ Insulin sensitivity can change hour to hour


→ Median likely outcome being approximately no change






INSULIN SENSITIVITY - Forecasting


SI



The Noble Steed



SI: Insulin Sensitivity!




The 95th percentile of SI in particular is useful for quantifying risk of increase in sensitivity




INSULIN SENSITIVITY - Forecasting


SI



The Noble Steed




SI: Insulin Sensitivity!






INSULIN SENSITIVITY - Forecasting


SI



The Noble Steed



SI: Insulin Sensitivity!



Using the 95th percentile of SI we can calculate the 5th percentile of BG for a given treatment



INSULIN SENSITIVITY – Selecting Treatments


Thus we can **directly quantify risk of hypo glycaemia** *and* select a treatment that manages this risk and **maximizes the overlap between likely outcomes and a target band**




The Hero



GRYPHON



How do we use GRYPHON clinically?



The Hero



GRYPHON

Patient
MOUSE, Micky ABC123

Actions

Calculate treatment

Stop STAR

Details

BG 8.9 mmol/L at 18:58
Next BG at 21:58
BG target range: 4.4 - 8.0 mmol/L

Insulin 0.28 mL/hr
(0.07 U/kg/hr)
Variable

Nutrition

4 IV glucose sources

	TPN (10% dextrose)	1.00 mL/hr
Parenteral	Morphine (5% dextrose)	0.25 mL/hr
	Dobutamine (10% dextrose)	0.10 mL/hr
	Dobutamine (5% dextrose)	0.15 mL/hr


Regimen: 1.0mL hourly

Enteral

1.0mL EBM hourly

Feeds scheduled: 1.00mL at 19:00 & 20:00 & 21:00

Select patient Patient history



Inputting data...



- Tablet computer interface
- Interface designed for clarity and ease of use
- Minimal data entry



How do we use GRYPHON clinically?

Calculating ...

Nutrition

Insulin


BG measurement

Nurse inputs current data into tablet interface

Work out how sensitive to insulin the patient is

$$\begin{aligned}\dot{G} &= -p_e G(t) - S_I G(t) \frac{Q(t)}{1 + \alpha_G Q(t)} + \frac{P(t) + EGP * m_{body} - CNS * m_{body}}{V_{g,frac}(t) * m_{body}} \\ \dot{I} &= -\frac{n_{2,I}(t)}{1 + \alpha_I I(t)} - n_{K,I}(t) - n_I(I(t) - Q(t)) + \frac{u_{en}(t)}{V_{I,frac} * m_{body}} \\ &\quad + (1 - x_L) \frac{u_{en}}{V_{I,frac} * m_{body}} \\ \dot{Q} &= n_I(I(t) - Q(t)) - n_C \frac{Q(t)}{1 + \alpha_Q Q(t)} \\ \dot{P}_1 &= -d_1 P_1 + P(t) \\ \dot{P}_2 &= -\min(d_2 P_2, P_{max}) + d_1 P_1 \\ P(t) &= \min(d_2 P_2, P_{max}) + PN(t) \\ u_{en} &= I_B e^{-\frac{d_2 u_{max}}{V_I}}\end{aligned}$$

MODEL



For each treatment **insulin sensitivity over the last few hours is calculated** based on BG response to nutrition and insulin inputs



The Hero



GRYPHON

How do we use GRYPHON clinically?

Calculating more stuff...

Nutrition

Insulin

BG measurement


Nurse inputs current data into tablet interface

Work out how sensitive to insulin the patient is


Predict how that sensitivity is going to change over the next few hours

$$\begin{aligned}\dot{G} &= -p_e G(t) - S_I G(t) \frac{Q(t)}{1 + \alpha_G Q(t)} + \frac{P(t) + EGP * m_{body} - CNS * m_{brain}}{V_{g,frac}(t) * m_{body}} \\ i &= -\frac{n_k I(t)}{1 + \alpha_I I(t)} - n_k I(t) - n_k (I(t) - Q(t)) + \frac{u_{em}(t)}{V_{l,frac} * m_{body}} \\ &\quad + (1 - x_L) \frac{u_{em}}{V_{l,frac} * m_{body}} \\ \dot{Q} &= n_k (I(t) - Q(t)) - n_c \frac{Q(t)}{1 + \alpha_Q Q(t)} \\ \dot{P}_1 &= -d_1 P_1 + P(t) \\ \dot{P}_2 &= -\min(d_2 P_2, P_{max}) + d_1 P_1 \\ P(t) &= \min(d_2 P_2, P_{max}) + P_N(t) \\ u_{em} &= I_B e^{-\frac{S_I u_{max}}{S_I}}\end{aligned}$$

MODEL



Statistical forecasts a range of likely insulin sensitivity changes



The Hero



GRYPHON



How do we use GRYPHON clinically?

Still calculating ...

Nutrition

Insulin

BG measurement

Nurse inputs current data into tablet interface


Work out how sensitive to insulin the patient is

Predict how that sensitivity is going to change over the next few hours

Predicted changes in SI used to guide the **CONTROL PROTOCOL** to select an optimum insulin treatment

$$\begin{aligned}
 \dot{G} &= -p_1 G(t) - S_1 G(t) + \frac{P(t) \cdot m_{BG} - G(t) \cdot m_{BG}}{V_{BG} \cdot m_{BG}} \\
 I &= -\frac{u_1(t)}{1 + u_1(t)} - u_2(t) - u_3(t) - u_4(t) + \frac{u_5(t)}{V_{IS} \cdot m_{IS}} \\
 \dot{G} &= u_1(t) - \dot{G}(t) - u_2(t) - u_3(t) - u_4(t) + \frac{u_5(t)}{V_{IS} \cdot m_{IS}} \\
 \dot{I} &= -d_1 I + P(t) \\
 \dot{P}(t) &= \min(d_2 P, P_{max}) + d_3 P \\
 P(t) &= \min(d_2 P, P_{max}) + P(t) \\
 u_5 &= \frac{1}{1 + e^{-\frac{G(t) - G_{target}}{s}}}
 \end{aligned}$$

MODEL



Predicted changes in Insulin Sensitivity are used to **choose an insulin treatment** such that **95% of BG outcomes** are likely to be **greater than a lower target**



The Hero



GRYPHON




How do we use GRYPHON clinically?



The Hero



GRYPHON



Now I make recommendations

Reviewing treatments




How do we use GRYPHON clinically?



The Hero



GRYPHON



Treatments are given.

After a chosen measurement interval, another BG measurement is taken, and another treatment is calculated.

Giving treatment





Christchurch Women's Hospital, NICU

Starting Criteria:

- 2 sequential BG greater than 10 mmol/L

BG measures

- Measures BG approximately every 4 hours
- Max time between measurements while on STAR is 6 hours
- Blood drawn from umbilical arterial line or heel prick
- Blood glucose is measured using blood gas





Christchurch Women's Hospital, NICU

Nutrition

- Is clinically determined and not modified by STAR
- Predominantly TPN, some medications are combined with a 5% Dextrose solution
- Start EBM (Expressed Breast Milk) as soon as it is available at a rate of 0.5mL every 4 hours

Insulin

- Shares a IV line with main dextrose fluids
- Insulin typically totals 1-5mL/day and is not considered in fluid targets





Christchurch Women's Hospital, NICU

STAR-NICU
Initial protocol implementation

STAR-GRYPHON
Optimised protocol

August 2008

August 2010

January 2013


Present

STAR used as a standard of care





STAR GRYPHON: optimizing the framework




First Implementation: STAR-NICU

- Target median to 6.0 mmol/L, with checks on the lower 5th
- Pilot trials
- Implemented as a standard of care


Optimised protocol:

STAR-GRYPHON


- Target 5th percentile of BG to ~4.4 mmol/L
- Maximum overlap of outcomes with target range



Christchurch – Clinical Results



	CCH - Retrospective	CCH – STAR NICU	CCH – STAR GRYPHON
Num episodes	25	61	14
Total hours	3098 s	5104	965
Measurement Interval (hrs)	3.2 [2.7 - 3.8]	3.2 [2.6 - 3.9]	4.0 [3.9 - 4.1]
Median insulin rate [IQR] (U/kg/hr)	0.031 [0.015 - 0.060]	0.044 [0.017 - 0.080]	0.05 [0.04 - 0.07]
Median Glucose rate [IQR] (mg/kg/hr)	8.1 [5.7 - 9.7]	7.4 [5.2 - 8.6]	7.6 [7.1 - 8.4]
Median BG [IQR] (mmol/L)	7.8 [6.5 - 9.1]	6.6 [5.5 - 8.1]	6.9 [6.1 - 7.7]
% BG within 4.0 - 8.0 mmol/L	51.9	69.8	80
% BG > 10 mmol/L	16.3	10.0	3.8
% BG < 4.0 mmol/L	2.1	3.5	0.1
% BG < 2.6 mmol/L	0.1	0.2	0
Num patients < 2.6 mmol/L	1	8	0



The
Happy Ending



Christchurch – now receiving **better control with fewer BG measurements**
Low rates of hypoglycaemia – severe hypos of BG<2.0 mmol/L are never seen



Christchurch –our most recent patient...





Patient history

All

48 hours



24 hours

12 hours




Back

View tables





Christchurch – Clinical Results



	STAR- NICU	STAR- GRYPHON	NIRTURE <small>Beardsall et al</small>	HINT <small>Alsweiler et al</small>	Comparing birth weights <small>Ng et al</small>
			Early insulin	Tight control	ELBW vs. LBW
Median BG [IQR]	6.6 [5.5- 8.2]	6.9 [6.1 - 7.7]	6.2±1.4	5.8 [4.8-6.7]	12 [6-24] and 11 [7-19]
% patients < 2.6 mmol/L	13%	0%	29%	58%	11-15%



The
Happy Ending




- Comparison difficult due to
- Differing definitions of hyper glycaemia
 - Differing protocols and targets

However, **GRYPHON shows less hypoglycaemia** than other studies, and tighter BG around the median



Christchurch – Clinical Results



The
Happy Ending




Better control → Improved outcomes
and survival rates

→ Healthier patients → Happier
doctors & parents!



A glycaemic control fairy tale?



The damsel
in distress



The evil
Stepmother



Abnormal
Blood sugar




The Hero



GRYPHON



The
Noble Steed



SI: Insulin Sensitivity!




The
Happy Ending



A STAR glycaemic control framework



Acknowledgements: The cast of extras



Canterbury
District Health Board
Te Pōari Hauora o Waitaha



**Prof. Geoff
Chase**




**Dr Adrienne
Lynn**



**Cameron
Gunn**



**Liam
Fisk**



**Dr Aaron
Le Compte**



**Dr Chris
Pretty**



**The UC
BioEng Crew**



Acknowledgement

This work was supported by EU FP7 IRSES (FP7-PEOPLE-2012-IRSES) program, project title: eTime - Engineering Technology-based Innovation in Medicine, Grant No. 318943.



Any Questions?

